Stop Overstocking: How Patent Intelligence Helps Wholesalers Reduce Branded Drug Inventory Risk
You probably already know the number: 80 to 90 percent. That’s how much of a branded small-molecule drug’s revenue can […]
The Hidden Hiring Signal: What Patent Cliff Events Tell You About Workforce Shifts in Big Pharma
Before a pharmaceutical company files a single WARN notice, before a restructuring plan hits an SEC filing, before a CEO
Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines
Colchicine cost nine cents a pill for more than two centuries. Then, in 2009, a company ran a 185-patient trial
Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines Read Post »
Biosimilar Sourcing 101: Use Patent and Exclusivity Data to Plan Your Switch Strategy
Every biosimilar switch strategy that fails, fails at the same point: someone made a sourcing decision based on the manufacturer’s
Biosimilar Sourcing 101: Use Patent and Exclusivity Data to Plan Your Switch Strategy Read Post »
Patent Citations: The Recruiter’s Guide to Finding Pharma’s Best Scientists
How life sciences talent teams can map influence networks, identify hidden innovators, and outmaneuver competitors using publicly available IP data
Patent Citations: The Recruiter’s Guide to Finding Pharma’s Best Scientists Read Post »
Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines
Colchicine cost nine cents a pill for more than two centuries. Then, in 2009, a company ran a 185-patient trial
Old Drugs, New Prices: How Pharma Justifies Premium Pricing for Repurposed Medicines Read Post »
Beyond the Third Wheel Rule: How Patent Filings Predict Russia’s API and Full-Cycle Drug Production Push
The conventional wisdom about Russia’s pharmaceutical market runs something like this: foreign companies localize drug packaging in Russia to comply
Europe’s Divisional Patent Game: How Big Pharma Avoids Final Decisions to Block Generics
The pharmaceutical patent landscape in Europe has shifted in ways that most of the industry’s public commentary has missed. The
Europe’s Divisional Patent Game: How Big Pharma Avoids Final Decisions to Block Generics Read Post »
505(b)(2) Approval Strategy: The Complete Step-by-Step Guide to a Successful NDA Submission
The 505(b)(2) pathway is the pharmaceutical industry’s most capital-efficient regulatory route, and it is widely misunderstood. Ask ten drug developers
